Describes the financing and growth decisions facing Direvo, a young German biotech firm with a customer/partner that wants to become an investor. Also discusses the business model for Direvo's directed evolution technology, with applications in both industrial enzymes and pharmaceutical products, either through partnerships or its own product development, with very different risk/return structures. The resulting hybrid business model is a constant source of discussion between the Direvo management team and the lead investor, Techno Venture Management. How should Direvo extract value from the spectrum of business options to develop an optimal exit strategy?